Clinical Trials
2 trialsNCT05561634 2025-09-30
RADIOSONIC
University Hospital, Lille
Phase 2 Recruiting
NCT03220009 2018-10-03
Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
National Cancer Institute (NCI)
Phase 2 Withdrawn